| 11C-OMAR and PET determined myocardial cannabinoid type 1 receptor upregulation in obesity:-a translational approach I Valenta, Z Varga, R Cinar, G Kunos, P Pacher, T Schindler Journal of Nuclear Medicine 58 (supplement 1), 582-582, 2017 | | 2017 |
| 24 The Endocannabinoid System and Cardiovascular Disease P Pacher, G Kunos Abdominal Obesity and the Endocannabinoid System: From Basic Aspects to …, 2008 | 1 | 2008 |
| 249 Enabling a systems biology approach to immunology: focus on innate immunity REW Hancock, G Haskó, B Csóka, ZH Németh, ES Vizi, P Pacher, F Tuluc, ... | | |
| 255 Quantifying the impact of transporters on cellular drug permeability P Lundquist, JR Wisniewski, M Kansy, P Artursson, ITG da Silva, ... | | |
| 326 Can the electrophysiological actions of antipsychoptic risperidone explain its cardiac side effects? V Kecskemeti, J Magyar, T Banyasz, ZS Bagi, P Pacher, N Szentandrassy, ... European Journal of Heart Failure Supplements 2, 60-61, 2003 | | 2003 |
| 329 CD95 in cancer: tool or target? L Antonioli, P Pacher, ES Vizi, G Haskó, A Deleersnijder, M Gerard, ... | | |
| 387 BAT: a new target for human obesity? N Sáinz, P Garrastachu, MJ García-Velloso, HU Zeilhofer, H Möhler, ... | | |
| 41 Characterization of a novel mouse model of hepatic cardiomyopathy BT Nemeth, C Matyas, ZV Varga, T Radovits, B Merkely, P Pacher European Heart Journal 38 (suppl_1), ehx501. 41, 2017 | | 2017 |
| 565 Changes in myocardial electrophysiological parameters and sensitivity to drugs in rodent experimental diabetes models V Kecskemeti, P Pacher, N Iost, L Virag, CS Lengyel, E Kocsis, A Varro European Journal of Heart Failure Supplements 4, 126-126, 2005 | | 2005 |
| 59 Power2: The power of yeast genetics applied to the powerhouse of the cell C Ohlsson, K Sjögren, P Bai, L Nagy, T Fodor, L Liaudet, P Pacher, ... | | |
| 62. A MENDELIAN RANDOMIZATION STUDY OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 INHIBITION AND STROKE: EVIDENCE FOR BENEFITS BEYOND LOW-DENSITY LIPOPROTEIN CHOLESTEROL LOWERING L Park, D Rosoff, L Mavromatis, A Bell, A Hamandi, J Jung, J Wagner, ... European Neuropsychopharmacology 75, S89, 2023 | | 2023 |
| 8-oxoguanine DNA glycosylase (OGG-1) regulates systemic inflammation induced by bacterial lipopolysacch JG Mabley, R Wallace, A Deb, P Pacher, R Elder, C Szabo FASEB JOURNAL 18 (4), A552-A553, 2004 | | 2004 |
| A highly potent, orally bioavailable pyrazole-derived cannabinoid CB2 receptor-selective full agonist for in vivo studies A Chicca, D Batora, C Ullmer, A Caruso, J Fingerle, T Hartung, R Degen, ... bioRxiv, 2024.04. 26.591311, 2024 | | 2024 |
| A mechanistic review of cell death in alcohol‐induced liver injury S Wang, P Pacher, RC De Lisle, H Huang, WX Ding Alcoholism: Clinical and Experimental Research 40 (6), 1215-1223, 2016 | 125 | 2016 |
| A monoacylglycerol lipase inhibitor showing therapeutic efficacy in mice without central side effects or dependence M Jiang, MCW Huizenga, JL Wirt, J Paloczi, A Amedi, RJ van den Berg, ... Nature Communications 14 (1), 8039, 2023 | 3 | 2023 |
| A new cannabinoid CB2 receptor agonist HU‐910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia/reperfusion injury B Horváth, L Magid, P Mukhopadhyay, S Bátkai, M Rajesh, O Park, ... British journal of pharmacology 165 (8), 2462-2478, 2012 | 132 | 2012 |
| A new, potent poly (ADP-ribose) polymerase inhibitor improves cardiac and vascular dysfunction associated with advanced aging P Pacher, A Vaslin, R Benkő, JG Mabley, L Liaudet, G Haskó, A Marton, ... Journal of Pharmacology and Experimental Therapeutics 311 (2), 485-491, 2004 | 97 | 2004 |
| A novel class of potent non-purine based xanthine oxidase inhibitors: antihyperuricemic and hepatoprotective effects A Nivorozhkin, JG Mabley, P Pacher, HS Li, AL Salzman, C Szabó, ... FASEB JOURNAL 17 (4), A253-A253, 2003 | 1 | 2003 |
| A novel poly (ADP-ribose) polymerase inhibitor, PJ34, improves cardiac function and vascular relaxation in rat model of chronic heart failure P Pacher, L Liaudet, JG Mabley, C Szabo FASEB JOURNAL 16 (4), A176-A176, 2002 | | 2002 |
| A novel ultrapotent poly (ADP-ribose) polymerase inhibitor improves cardiac and endothelial dysfunction associated with aging-induced heart failure P Pacher, R Benko, A Vaslin, JG Mabley, L Liaudet, G Hasko, M Kollai, ... FASEB JOURNAL 18 (5), A1191-A1191, 2004 | | 2004 |
george haskoColumbia University在 cumc.columbia.edu 的电子邮件经过验证
